Research programme: adenosine A2 receptor antagonists - Almirall SA/Neurocrine Biosciences

Drug Profile

Research programme: adenosine A2 receptor antagonists - Almirall SA/Neurocrine Biosciences

Alternative Names: NBI 80649

Latest Information Update: 28 Feb 2011

Price : $50

At a glance

  • Originator Almirall-Prodesfarma; Neurocrine Biosciences
  • Developer Almirall S.A.; Neurocrine Biosciences
  • Class Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Huntington's disease; Parkinson's disease

Most Recent Events

  • 28 Feb 2011 Development discontinued for Huntington's disease before 2011
  • 28 Feb 2011 Development discontinued for Parkinson's disease before 2011
  • 07 Nov 2007 Pharmacodynamics and adverse events data from a preclinical study in Parkinson's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top